Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence-Reference-Cited by-同舟云学术

Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence

Published:2022-05 Issue: Volume:Volume 16 Page:1307-1319
ISSN:1177-889X
Container-title:Patient Preference and Adherence
language:en
Short-container-title:PPA

Author:

Sabsabi Sajida,Mikhael Elio,Jalkh Georges,Macaron Gabrielle^ORCID,Rensel Mary^ORCID

Publisher

Informa UK Limited

Subject

Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Social Sciences (miscellaneous),Medicine (miscellaneous)

Reference88 articles.

1. Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis

2. Axonal Transection in the Lesions of Multiple Sclerosis

3. Multiple sclerosis

4. Long‐term evolution of multiple sclerosis disability in the treatment era

5. Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fluorine in the pharmaceutical industry: Synthetic approaches and application of clinically approved fluorine-enriched anti-infectious medications;European Journal of Medicinal Chemistry;2024-05

2. 1-Phosphate receptor agonists: A promising therapeutic avenue for ischemia-reperfusion injury management;International Immunopharmacology;2024-04

3. Sphingosine-1-Phosphate Receptor Modulator – Siponimod: An Evaluation to Ameliorate Aluminium Chloride Induced Behavioural Change and Biochemical effects;Research Journal of Pharmacy and Technology;2024-01-19

4. Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programme;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2024-01

5. Progressive multiple sclerosis treatment considerations in the UK: Experience from trials and real-world population;Advances in Clinical Neuroscience & Rehabilitation;2024